Evidence map›Paper›PMID 40634284›Full record

ArticleCell death & disease2025

Therapeutic targeting of FOSL1 and RELA-dependent transcriptional mechanisms to suppress pancreatic cancer metastasis.

Joana E Aggrey-Fynn, Meghana Manjunath, Ashish Rajput, Amro M Abdelrahman, Julia Thiel, Mark J Truty, Andrew Clark, Meng Dong, Steven A Johnsen

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Multi-omics characterization of a GPRC5AJournal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joana E Aggrey-FynnRobert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany.
Meghana ManjunathRobert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany.
Ashish RajputRobert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany.
Amro M AbdelrahmanDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9865-0551
Julia ThielDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology and University of Tübingen, Stuttgart, Germany.ORCID http://orcid.org/0009-0003-5437-8498
Mark J TrutyDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Andrew ClarkInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Meng DongDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology and University of Tübingen, Stuttgart, Germany.ORCID http://orcid.org/0000-0002-6434-1678
Steven A JohnsenRobert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany. steven.johnsen@bosch-health-campus.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer often diagnosed at an advanced stage, leading to a poor prognosis. The tumor microenvironment (TME) plays a crucial role in driving metastasis, with inflammatory signaling pathways contributing to tumor progression and therapy resistance. However, the combined effects of inflammatory and oncogenic signaling on the epigenetic regulation of PDAC metastasis are poorly understood. Here, we demonstrate that tumor necrosis factor-alpha (TNFα) and epidermal growth factor (EGF) signaling converge to regulate PDAC cell migration through the activation of NF-κB and AP-1 transcription factors. Using single-cell RNA sequencing, in vitro and in vivo models, we show that the simultaneous activation of these pathways with TNFα and EGF cooperatively induces the expression of genes associated with cell motility and migration. Consistently, combinatorial induced genes are co-regulated by the transcription factors FOSL1 and RELA. Remarkably, inhibition of NF-κB transcriptional activity with a glucocorticoid receptor (GR) mixed agonist significantly reduced PDAC cell migration by decreasing RNA polymerase II recruitment to target genes. These findings reveal a novel mechanism by which inflammatory and oncogenic pathways cooperate to drive PDAC metastasis and highlight the therapeutic potential of GR agonists in mitigating tumor cell migration. Our study offers promising avenues for developing mechanism-based therapeutic strategies in PDAC management.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins c-fosTranscription Factor RelATranscription, GeneticAnimalsCell Line, TumorCell MovementEpidermal Growth FactorFos-Related Antigen 1Gene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisNF-kappa BSignal TransductionEpidermal Growth FactorFos-Related Antigen 1NF-kappa BProto-Oncogene Proteins c-fosRELA protein, humanTranscription Factor AP-1Transcription Factor RelATumor Necrosis Factor-alpha

Identifiers

PMID40634284
PMCPMC12241458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.